DCAL Dishman Carbogen Amcis Q3 FY25 results (Oct–Dec 2024) and concall
Dishman Carbogen Amcis reported a strong Q3 FY25, driven by significant EBITDA growth and improved operating margins. The company is progressing with its French drug product facility, expecting GMP certification soon, and is reinforcing synergies across its global operations. Despite some challenges like increased finance costs due to covenant breaches, management is optimistic about future growth and margin expansion, targeting 24-25% EBITDA margin by FY28.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 93 | 97 |
| EBITDA | 13 | 23 |
| Net profit | 14 | -13 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
